EYEPOINT INC (EYPT) Stock Price, Forecast & Analysis
NASDAQ:EYPT • US30233G2093
EYPT Key Statistics, Chart & Performance
The current stock price of EYPT is 15.33 USD. In the past month the price decreased by -6.15%. In the past year, price increased by 149.27%.
EYPT Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to EYPT. When comparing the yearly performance of all stocks, EYPT is one of the better performing stocks in the market, outperforming 95.31% of all stocks.
EYPT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EYPT. While EYPT has a great health rating, there are worries on its profitability.
EYPT Financial Highlights
Over the last trailing twelve months EYPT reported a non-GAAP Earnings per Share(EPS) of -2.99. The EPS decreased by -49.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.75% | ||
| ROE | -102.78% | ||
| Debt/Equity | 0 |
EYPT Forecast & Estimates
18 analysts have analysed EYPT and the average price target is 36.81 USD. This implies a price increase of 140.08% is expected in the next year compared to the current price of 15.33.
For the next year, analysts expect an EPS growth of -33.91% and a revenue growth -25.48% for EYPT
EYPT Ownership
EYPT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.08 | 954.38B | ||
| JNJ | JOHNSON & JOHNSON | 20.81 | 584.231B | ||
| MRK | MERCK & CO. INC. | 22.6 | 303.452B | ||
| PFE | PFIZER INC | 8.87 | 151.524B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.97 | 123.489B | ||
| ZTS | ZOETIS INC | 18.75 | 56.752B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.045B | ||
| VTRS | VIATRIS INC | 6.29 | 18.336B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.89 | 12.412B | ||
| AXSM | AXSOME THERAPEUTICS INC | 224.33 | 9.261B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EYPT
Company Profile
EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 165 full-time employees. The company went IPO on 2005-01-27. The firm is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Company Info
EYEPOINT INC
480 Pleasant Street, Suite C400
Watertown MASSACHUSETTS 02472 US
CEO: Nancy Lurker
Employees: 165
Phone: 16179265000
EYEPOINT INC / EYPT FAQ
What does EYEPOINT INC do?
EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 165 full-time employees. The company went IPO on 2005-01-27. The firm is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
What is the stock price of EYEPOINT INC today?
The current stock price of EYPT is 15.33 USD. The price increased by 4.29% in the last trading session.
Does EYPT stock pay dividends?
EYPT does not pay a dividend.
What is the ChartMill technical and fundamental rating of EYPT stock?
EYPT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Who owns EYEPOINT INC?
You can find the ownership structure of EYEPOINT INC (EYPT) on the Ownership tab.
What is the Short Interest ratio of EYEPOINT INC (EYPT) stock?
The outstanding short interest for EYEPOINT INC (EYPT) is 11.14% of its float.